ClinicalTrials.gg
Active, not recruitingNCT06655896Updated Sep 2, 2026

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

A Phase 2 interventional study of rapcabtagene autoleucel and rituximab in Scleroderma, Diffuse, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 93 sites in 22 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 153 studies in Scleroderma, Diffuse with a site in United States — 29 open to participants now, 39 under way, 5 of them phase 3. Scleroderma, Diffuse · United States.

Planned enrollment
28th of 120
96 · median 29
Started
2024
with 10 others
Phase 2
41 of 153
8 open now
Primary completion
2028-11
later than 25 of 38 live
Registered
135th of 153
by date
Lead sponsor
3 of 153
Novartis Pharmaceuticals

Among the 153 studies in Scleroderma, Diffuse with a site in United States, this one is the 28th largest by planned enrollment of the 120 interventional ones that give a count, is one of 11 that started in 2024, is one of 41 in phase 2, reaches primary completion later than 25 of the 38 other live ones, and was the 135th registered.

Scleroderma, Diffuse

310 studies on the registry are indexed under Scleroderma, Diffuse; 76 are open to participants now.

Browse Scleroderma, Diffuse studies →

Open to participants now

29 of the 153 studies in Scleroderma, Diffuse with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Scleroderma, Diffuse studies recruiting now, 28 (51%) set no upper age limit and 20 (36%) stop at 75 or younger; 10 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Scleroderma, Diffuse with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

Read the detailed description

This is a phase 2, multi-part, five-year, randomized, open-label, assessor-blinded, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab in participants with severe refractory diffuse cutaneous systemic sclerosis (dcSSc). This study comprises two cohorts:

  • A Lead-in Cohort enrolling participants to receive rapcabtagene autoleucel.
  • A Randomized Cohort enrolling participants to receive rapcabtagene autoleucel or rituximab. Participants in the rituximab arm whose disease is not fully controlled may receive rapcabtagene autoleucel treatment once the participant is confirmed to be eligible per protocol.

After end of study, participants who received rapcabtagene autoleucel infusion will enter a long-term follow-up (LTFU) period after rapcabtagene autoleucel infusion. This LTFU will be described in a separate study protocol.

03

Conditions studied

  • Scleroderma, Diffuse

Browse trials for

Keywords

  • Diffuse cutaneous systemic sclerosis (dcSSc)
  • Scleroderma, Diffuse
  • revised Composite Response Index in Systemic Sclerosis (rCRISS)
  • modified Rodnan skin score (mRSS)
  • forced vital capacity (FVC)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must fulfill the 2013 American College of Rheumatology/ European League Against Rheumatism classification criteria for systemic sclerosis and meet the diffuse cutaneous SSc (dcSSc) subset classification according to LeRoy.
  2. Disease onset from the first non-Raynaud symptoms attributable to SSc (e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea) within 7 years prior to the Screening visit.
  3. Severe, progressive systemic sclerosis disease defined by at least one of the following:

    • Progressive systemic sclerosis-associated interstitial lung disease
    • Severe, progressive systemic sclerosis skin disease
    • systemic sclerosis-associated cardiac involvement at Screening
  4. All recommended vaccinations received according to institutional, local or global guidelines for immuno-compromised patients.

Exclusion criteria

Exclusion Criteria:

  1. Any condition during Screening that could prevent a complete washout of medications as required per protocol or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study, as judged by the Investigator.
  2. Participants with history of to in rapcabtagene autoleucel or to rituximab.
  3. Any participant for whom treatment with rituximab is clinically inappropriate in the opinion of the investigator.
  4. Any medical conditions that are not related to SSc that, in the opinion of the Investigator, would jeopardize the ability of the participant to tolerate lymphodepletion and anti-CD19 CAR-T cell therapy.
  5. Rheumatic disease other than dcSSc, (except secondary Sjogren's syndrome or scleroderma myopathy),including limited cutaneous systemic sclerosis (lcSSc) or sine scleroderma at Screening.
  6. Participants with pre-existing pulmonary hypertension.
  7. Significant renal pathology at Screening.
  8. Participants with uncontrolled stage II hypertension at Screening.
  9. Vaccination with within 6 weeks prior to randomization.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    rapcabtagene autoleucel arm

    rapcabtagene autoleucel

    Biological: rapcabtagene autoleucel

  • Active comparator
    rituximab arm

    rituximab

    Biological: rituximab

Interventions

  • single infusion of rapcabtagene autoleucel after lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.

  • Biologicalrituximab

    rituximab intravenous infusion (i.v.) as per protocol

06

What researchers measure

Primary outcomes

  1. Achievement of a treatment response as per the Revised Composite Response Index in Systemic Sclerosis 50 (rCRISS50) definition at Week 52.

    To demonstrate the superiority of rapcabtagene autoleucel as a single infusion compared to rituximab, with respect to the proportion of participants achieving a Revised Composite Response Index in Systemic Sclerosis 50 (rCRISS50) response at Week 52. This response is assessed across 5 assessment domains: (1) modified Rodnan Skin Score (mRSS), (2) Health Assessment Questionnaire Disability Index (HAQ-DI), (3) patient global assessment (PGA), (4) physician global assessment (PhGA) and (5) percent-predicted forced vital capacity (FVC%).

    Time frame: Week 52

Secondary outcomes

  1. Change from baseline in Forced Vital Capacity (FVC)% predicted at Week 52

    Change from baseline in FVC % predicted

    Time frame: Baseline, Week 52

  2. Change from baseline in modified Rodnan Skin Score (mRSS) at Week 52.

    The modified Rodnan Skin Score (mRSS) is a clinical tool used to assess skin thickness in patients with systemic sclerosis (scleroderma). It involves palpating the skin and rating its thickness on a scale from 0 to 3 across 17 different body sites. The total score is the sum of the individual scores from all 17 sites, ranging from 0 (normal) to 51 (severe).

    Time frame: Baseline, Week 52

  3. Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52.

    The Health Assessment Questionnaire Disability Index (HAQ-DI) is a widely used tool to measure a patient's level of functional ability and disability. It consists of 20 questions that cover eight domains of daily living activities: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each question is rated on a scale from 0 (without difficulty) to 3 (unable to do).

    Time frame: Baseline, Week 52

  4. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The distribution of adverse events will be done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs) through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: Up to end of study, assessed up to approximately 5 years

07

Study locations

93 sites
  • UCLA
    Los Angeles, California 90095, United States
  • UCSF
    San Francisco, California 94115, United States
  • Sutter Health Network
    San Pablo, California 94806, United States
  • FL Medical Clinic Orlando Health
    Zephyrhills, Florida 33542, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University Of Iowa
    Iowa City, Iowa 52242, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Michigan Med University of Michigan
    Ann Arbor, Michigan 48109-5271, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • James Cancer Hospital
    Columbus, Ohio 43210, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Avera Cancer
    Sioux Falls, South Dakota 57105, United States
  • LDS Hospital
    Salt Lake City, Utah 84143, United States
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016KEH, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Vienna, 1140, Austria
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Salvador, Estado de Bahia 41253-190, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 80030-110, Brazil
  • Novartis Investigative Site
    Barretos, São Paulo 14784-400, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01232-010, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01308-050, Brazil
  • Novartis Investigative Site
    Olomouc, 779 00, Czechia
  • Novartis Investigative Site
    Prague, 128 00, Czechia
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75014, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Strasbourg, 67091, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06120, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Nuremberg, 90419, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Pescara, PE 65124, Italy
  • Novartis Investigative Site
    Perugia, PG 06129, Italy
  • Novartis Investigative Site
    Pisa, PI 56126, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608648, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 9808574, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 1138603, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Ishikawa, 9208641, Japan
  • Novartis Investigative Site
    Kyoto, 6068507, Japan
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
  • Novartis Investigative Site
    Seoul, 04763, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Málaga, 29010, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Geneva, 1211, Switzerland
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Nov 2028, 49 months after the start.

Of 24 phase 2 interventional studies under Scleroderma, Diffuse, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 108. This study's planned 49 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 24, 2024
StartActual
Oct 29, 2024
Primary completionEst.
Nov 30, 2028
CompletionEst.
Aug 30, 2032
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06655896
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Oct 29, 2024
Primary completion
Nov 30, 2028 (estimated)
Completion
Aug 30, 2032 (estimated)
Last update
Sep 2, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rapcabtagene autoleucel

Start the discussion